Claudio Tripodo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1732922/publications.pdf

Version: 2024-02-01

36303 42399 9,707 182 51 92 citations g-index h-index papers 186 186 186 15570 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Colon Cancer Stem Cells Dictate Tumor Growth and Resist Cell Death by Production of Interleukin-4. Cell Stem Cell, 2007, 1, 389-402.	11.1	968
2	Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology, 2010, 51, 1158-1167.	7.3	371
3	Neutrophil extracellular traps mediate transfer of cytoplasmic neutrophil antigens to myeloid dendritic cells toward ANCA induction and associated autoimmunity. Blood, 2012, 120, 3007-3018.	1.4	350
4	CD4+CD25+ Regulatory T Cells Suppress Mast Cell Degranulation and Allergic Responses through OX40-OX40L Interaction. Immunity, 2008, 29, 771-781.	14.3	333
5	Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood, 2014, 124, 1715-1726.	1.4	288
6	C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation. Nature Communications, 2016, 7, 10346.	12.8	224
7	Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood, 2006, 107, 4643-4649.	1.4	217
8	Overexpression of interleukinâ€23, but not interleukinâ€17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis. Arthritis and Rheumatism, 2009, 60, 955-965.	6.7	215
9	Plasmacytoid dendritic cells promote systemic sclerosis with a key role for TLR8. Science Translational Medicine, 2018, 10, .	12.4	187
10	Mast cells counteract regulatory T-cell suppression through interleukin-6 and OX40/OX40L axis toward Th17-cell differentiation. Blood, 2009, 114, 2639-2648.	1.4	184
11	Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9. Journal of Experimental Medicine, 2010, 207, 2931-2942.	8.5	175
12	Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. Blood, 2011, 117, 1595-1604.	1.4	173
13	RNA recognition by human TLR8 can lead to autoimmune inflammation. Journal of Experimental Medicine, 2013, 210, 2903-2919.	8.5	167
14	RORC1 Regulates Tumor-Promoting "Emergency―Granulo-Monocytopoiesis. Cancer Cell, 2015, 28, 253-269.	16.8	154
15	CD38/CD31, the CCL3 and CCL4 Chemokines, and CD49d/Vascular Cell Adhesion Molecule-1 Are Interchained by Sequential Events Sustaining Chronic Lymphocytic Leukemia Cell Survival. Cancer Research, 2009, 69, 4001-4009.	0.9	153
16	Gamma-delta T-cell lymphomas. Nature Reviews Clinical Oncology, 2009, 6, 707-717.	27.6	152
17	<i>In vivo</i> Targeting of Human Neutralizing Antibodies against CD55 and CD59 to Lymphoma Cells Increases the Antitumor Activity of Rituximab. Cancer Research, 2007, 67, 10556-10563.	0.9	141
18	C1q as a unique player in angiogenesis with therapeutic implication in wound healing. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 4209-4214.	7.1	140

#	Article	IF	CITATIONS
19	An Alternative Role of C1q in Cell Migration and Tissue Remodeling: Contribution to Trophoblast Invasion and Placental Development. Journal of Immunology, 2010, 185, 4420-4429.	0.8	135
20	Gene expression analysis uncovers similarity and differences among Burkitt lymphoma subtypes. Blood, 2011, 117, 3596-3608.	1.4	128
21	Human Bone Marrow Mesenchymal Stem Cells Display Anti-Cancer Activity in SCID Mice Bearing Disseminated Non-Hodgkin's Lymphoma Xenografts. PLoS ONE, 2010, 5, e11140.	2.5	128
22	Mast Cell Targeting Hampers Prostate Adenocarcinoma Development but Promotes the Occurrence of Highly Malignant Neuroendocrine Cancers. Cancer Research, 2011, 71, 5987-5997.	0.9	124
23	CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death. Blood, 2011, 118, 6141-6152.	1.4	122
24	Mast cells enhance proliferation of B lymphocytes and drive their differentiation toward IgA-secreting plasma cells. Blood, 2010, 115, 2810-2817.	1.4	113
25	Osteopontin Shapes Immunosuppression in the Metastatic Niche. Cancer Research, 2014, 74, 4706-4719.	0.9	110
26	Compromised nuclear envelope integrity drives TREX1-dependent DNA damage and tumor cell invasion. Cell, 2021, 184, 5230-5246.e22.	28.9	109
27	MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease. Journal of Hepatology, 2016, 64, 682-690.	3.7	106
28	Defective Stromal Remodeling and Neutrophil Extracellular Traps in Lymphoid Tissues Favor the Transition from Autoimmunity to Lymphoma. Cancer Discovery, 2014, 4, 110-129.	9.4	100
29	MMP-13 stimulates osteoclast differentiation and activation in tumour breast bone metastases. Breast Cancer Research, 2011, 13, R105.	5.0	92
30	The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation. Haematologica, 2013, 98, 1115-1123.	3.5	92
31	How I diagnose and treat splenic lymphomas. Blood, 2011, 117, 2585-2595.	1.4	91
32	Mesenchymal Transition of High-Grade Breast Carcinomas Depends on Extracellular Matrix Control of Myeloid Suppressor Cell Activity. Cell Reports, 2016, 17, 233-248.	6.4	84
33	Decidual endothelial cells express surface-bound C1q as a molecular bridge between endovascular trophoblast and decidual endothelium. Molecular Immunology, 2008, 45, 2629-2640.	2.2	82
34	Mast Cells and Th17 Cells Contribute to the Lymphoma-Associated Pro-Inflammatory Microenvironment of Angioimmunoblastic T-Cell Lymphoma. American Journal of Pathology, 2010, 177, 792-802.	3.8	82
35	Drp1 Controls Effective T Cell Immune-Surveillance by Regulating T Cell Migration, Proliferation, and cMyc-Dependent Metabolic Reprogramming. Cell Reports, 2018, 25, 3059-3073.e10.	6.4	82
36	Release of naltrexone on buccal mucosa: Permeation studies, histological aspects and matrix system design. European Journal of Pharmaceutics and Biopharmaceutics, 2007, 67, 425-433.	4.3	78

3

#	Article	IF	Citations
37	miR-9 and miR-200 Regulate PDGFRÎ ² -Mediated Endothelial Differentiation of Tumor Cells in Triple-Negative Breast Cancer. Cancer Research, 2016, 76, 5562-5572.	0.9	74
38	The Aryl Hydrocarbon Receptor Modulates Acute and Late Mast Cell Responses. Journal of Immunology, 2012, 189, 120-127.	0.8	70
39	Human OX40 tunes the function of regulatory T cells in tumor and nontumor areas of hepatitis C virus-infected liver tissue. Hepatology, 2014, 60, 1494-1507.	7.3	70
40	Splenic marginal zone lymphoma with or without villous lymphocytes. Cancer, 2004, 101, 2050-2057.	4.1	67
41	Rheostatic Functions of Mast Cells in the Control of Innate and Adaptive Immune Responses. Trends in Immunology, 2017, 38, 648-656.	6.8	66
42	Angioimmunoblastic T-cell lymphoma. Critical Reviews in Oncology/Hematology, 2008, 68, 264-271.	4.4	64
43	The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study. Lancet Haematology,the, 2016, 3, e467-e479.	4.6	63
44	A nonâ€redundant role for OX40 in the competitive fitness of Treg in response to ILâ€2. European Journal of Immunology, 2010, 40, 2902-2913.	2.9	62
45	Exploring a regulatory role for mast cells: â€~MCregs'?. Trends in Immunology, 2010, 31, 97-102.	6.8	62
46	SPARC Oppositely Regulates Inflammation and Fibrosis in Bleomycin-Induced Lung Damage. American Journal of Pathology, 2011, 179, 3000-3010.	3.8	62
47	Exacerbated experimental autoimmune encephalomyelitis in mast-cell-deficient KitW-sh/W-sh mice. Laboratory Investigation, 2011, 91, 627-641.	3.7	61
48	Mast Cells Boost Myeloid-Derived Suppressor Cell Activity and Contribute to the Development of Tumor-Favoring Microenvironment. Cancer Immunology Research, 2015, 3, 85-95.	3.4	59
49	Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint Inhibitors. Clinical Cancer Research, 2017, 23, 5149-5161.	7.0	59
50	The abrogation of the HOXB7/PBX2 complex induces apoptosis in melanoma through the miRâ€221&222â€câ€FOS pathway. International Journal of Cancer, 2013, 133, 879-892.	5.1	55
51	Correlation between expression of cyclooxygenase-2 and the presence of inflammatory cells in human primary hepatocellular carcinoma: Possible role in tumor promotion and angiogenesis. World Journal of Gastroenterology, 2005, 11, 4638.	3.3	54
52	Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia. Blood, 2010, 116, 584-592.	1.4	51
53	Reproducibility of the WHO histological criteria for the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms. Modern Pathology, 2014, 27, 814-822.	5.5	48
54	Pathobiology of Hodgkin Lymphoma. Advances in Hematology, 2011, 2011, 1-18.	1.0	46

#	Article	IF	CITATIONS
55	The cumulative amount of serum-free light chain is a strong prognosticator in chronic lymphocytic leukemia. Blood, 2011, 118, 6353-6361.	1.4	45
56	C7 is expressed on endothelial cells as a trap for the assembling terminal complement complex and may exert anti-inflammatory function. Blood, 2009, 113, 3640-3648.	1.4	44
57	Stromal SPARC contributes to the detrimental fibrotic changes associated with myeloproliferation whereas its deficiency favors myeloid cell expansion. Blood, 2012, 120, 3541-3554.	1.4	44
58	Complement Protein C1q Binds to Hyaluronic Acid in the Malignant Pleural Mesothelioma Microenvironment and Promotes Tumor Growth. Frontiers in Immunology, 2017, 8, 1559.	4.8	44
59	Cross-Talk between Myeloid-Derived Suppressor Cells and Mast Cells Mediates Tumor-Specific Immunosuppression in Prostate Cancer. Cancer Immunology Research, 2018, 6, 552-565.	3.4	44
60	Chronic lymphocytic leukemia nurse-like cells express hepatocyte growth factor receptor (c-MET) and indoleamine 2,3-dioxygenase and display features of immunosuppressive type 2 skewed macrophages. Haematologica, 2014, 99, 1078-1087.	3.5	43
61	The bone marrow stroma in hematological neoplasms—a guilty bystander. Nature Reviews Clinical Oncology, 2011, 8, 456-466.	27.6	42
62	Class IIa HDACs repressive activities on MEF2â€depedent transcription are associated with poor prognosis of ER ⁺ breast tumors. FASEB Journal, 2013, 27, 942-954.	0.5	41
63	Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study. British Journal of Haematology, 2018, 183, 755-765.	2.5	41
64	HSPH1 inhibition downregulates Bcl-6 and c-Myc and hampers the growth of human aggressive B-cell non-Hodgkin lymphoma. Blood, 2015, 125, 1768-1771.	1.4	40
65	SOCS2 Controls Proliferation and Stemness of Hematopoietic Cells under Stress Conditions and Its Deregulation Marks Unfavorable Acute Leukemias. Cancer Research, 2015, 75, 2387-2399.	0.9	39
66	Mast cells are associated with the onset and progression of celiac disease. Journal of Allergy and Clinical Immunology, 2017, 139, 1266-1274.e1.	2.9	39
67	Molecular signature of Epstein Barr virus-positive Burkitt lymphoma and post-transplant lymphoproliferative disorder suggest different roles for Epstein Barr virus. Frontiers in Microbiology, 2014, 5, 728.	3.5	37
68	PDGFR \hat{I}^2 and FGFR2 mediate endothelial cell differentiation capability of triple negative breast carcinoma cells. Molecular Oncology, 2014, 8, 968-981.	4.6	37
69	Bone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphoma. Blood, 2014, 123, 1836-1849.	1.4	37
70	Poly(I:C) and CpG-ODN combined aerosolization to treat lung metastases and counter the immunosuppressive microenvironment. Oncolmmunology, 2015, 4, e1040214.	4.6	37
71	Common extracellular matrix regulation of myeloid cell activity in the bone marrow and tumor microenvironments. Cancer Immunology, Immunotherapy, 2017, 66, 1059-1067.	4.2	36
72	An automated image analysis methodology for classifying megakaryocytes in chronic myeloproliferative disorders. Medical Image Analysis, 2008, 12, 703-712.	11.6	35

#	Article	IF	CITATIONS
73	New Potential Therapeutic Approach for the Treatment of B-Cell Malignancies Using Chlorambucil/Hydroxychloroquine-Loaded Anti-CD20 Nanoparticles. PLoS ONE, 2013, 8, e74216.	2.5	34
74	Stromal niche communalities underscore the contribution of the matricellular protein SPARC to B-cell development and lymphoid malignancies. Oncolmmunology, 2014, 3, e28989.	4.6	34
75	SCD5â€induced oleic acid production reduces melanoma malignancy by intracellular retention of SPARC and cathepsin B. Journal of Pathology, 2015, 236, 315-325.	4.5	34
76	CD146+ bone marrow osteoprogenitors increase in the advanced stages of primary myelofibrosis. Haematologica, 2009, 94, 127-130.	3.5	33
77	Monocytes/macrophages but not T lymphocytes are the major targets of the CCL3/CCL4 chemokines produced by CD38 ⁺ CD49d ⁺ chronic lymphocytic leukaemia cells. British Journal of Haematology, 2010, 150, 111-112.	2.5	33
78	Mast Cells Control the Expansion and Differentiation of IL-10–Competent B Cells. Journal of Immunology, 2014, 193, 4568-4579.	0.8	33
79	Virus-encoded microRNA contributes to the molecular profile of EBV-positive Burkitt lymphomas. Oncotarget, 2016, 7, 224-240.	1.8	33
80	Oncogene-Driven Intrinsic Inflammation Induces Leukocyte Production of Tumor Necrosis Factor That Critically Contributes to Mammary Carcinogenesis. Cancer Research, 2010, 70, 7764-7775.	0.9	31
81	Bone marrow biopsy in Hodgkin's lymphoma. European Journal of Haematology, 2004, 73, 149-155.	2.2	30
82	Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target. Blood, 2011, 118, 4421-4430.	1.4	30
83	Peripheral T-cell lymphoma classification: the matter of cellular derivation. Expert Review of Hematology, 2011, 4, 415-425.	2.2	30
84	The soluble terminal complement complex (SC5b-9) up-regulates osteoprotegerin expression and release by endothelial cells: implications in rheumatoid arthritis. Rheumatology, 2008, 48, 293-298.	1.9	29
85	In Vivo Biodistribution and Lifetime Analysis of Cy5.5-Conjugated Rituximab in Mice Bearing Lymphoid Tumor Xenograft Using Time-Domain Near-Infrared Optical Imaging. Molecular Imaging, 2008, 7, 7290.2008.00028.	1.4	29
86	The matricellular protein SPARC supports follicular dendritic cell networking toward Th17 responses. Journal of Autoimmunity, 2011, 37, 300-310.	6.5	29
87	A variant of the <i>LRP4</i> gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome. British Journal of Haematology, 2011, 152, 284-294.	2.5	28
88	The Hepatic Expression of Vitamin D Receptor Is Inversely Associated With the Severity of Liver Damage in Genotype 1 Chronic Hepatitis C Patients. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 193-200.	3.6	28
89	High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steatohepatitis. Digestive and Liver Disease, 2011, 43, 404-410.	0.9	27
90	Mast Cells Infiltrating Inflamed or Transformed Gut Alternatively Sustain Mucosal Healing or Tumor Growth. Cancer Research, 2015, 75, 3760-3770.	0.9	27

#	Article	IF	Citations
91	Persistent Immune Stimulation Exacerbates Genetically Driven Myeloproliferative Disorders via Stromal Remodeling. Cancer Research, 2017, 77, 3685-3699.	0.9	27
92	A Spatially Resolved Dark-versus Light-Zone Microenvironment Signature Subdivides Germinal Center-Related Aggressive B Cell Lymphomas. IScience, 2020, 23, 101562.	4.1	27
93	The prognostic value of the myeloid-mediated immunosuppression marker Arginase-1 in classic Hodgkin lymphoma. Oncotarget, 2016, 7, 67333-67346.	1.8	27
94	Targeted tumor imaging of anti-CD20-polymeric nanoparticles developed for the diagnosis of B-cell malignancies. International Journal of Nanomedicine, 2015, 10, 4099.	6.7	26
95	Deoxycoformycin (pentostatin) in the treatment of splenic marginal zone lymphoma (SMZL) with or without villous lymphocytes. European Journal of Haematology, 2005, 75, 130-135.	2.2	25
96	Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study. Leukemia and Lymphoma, 2015, 56, 3281-3287.	1.3	25
97	Wnt3a Neutralization Enhances T-cell Responses through Indirect Mechanisms and Restrains Tumor Growth. Cancer Immunology Research, 2018, 6, 953-964.	3.4	25
98	Distinctive Histogenesis and Immunological Microenvironment Based on Transcriptional Profiles of Follicular Dendritic Cell Sarcomas. Molecular Cancer Research, 2017, 15, 541-552.	3.4	24
99	DNA damage response at telomeres boosts the transcription of SARSâ€CoVâ€2 receptor ACE2 during aging. EMBO Reports, 2022, 23, e53658.	4.5	24
100	The good and bad of targeting cancer-associated extracellular matrix. Current Opinion in Pharmacology, 2017, 35, 75-82.	3.5	23
101	Pathological Significance and Prognostic Value of Surfactant Protein D in Cancer. Frontiers in Immunology, 2018, 9, 1748.	4.8	23
102	Hematopoietic stem cell function in \hat{l}^2 -thalassemia is impaired and is rescued by targeting the bone marrow niche. Blood, 2020, 136, 610-622.	1.4	23
103	Associations between Notch-2, Akt-1 and HER2/neu Expression in Invasive Human Breast Cancer: A Tissue Microarray Immunophenotypic Analysis on 98 Patients. Pathobiology, 2007, 74, 317-322.	3.8	22
104	Use of intrapleural bortezomib in myelomatous pleural effusion. British Journal of Haematology, 2007, 139, 621-622.	2.5	22
105	Interleukin-17A promotes the growth of human germinal center derived non-Hodgkin B cell lymphoma. Oncolmmunology, 2015, 4, e1030560.	4.6	21
106	Long-lasting remission of primary hepatic lymphoma and hepatitis C virus infection achieved by the alpha-interferon treatment. The Hematology Journal, 2004, 5, 530-533.	1.4	20
107	An Update on the Xenograft and Mouse Models Suitable for Investigating New Therapeutic Compounds for the Treatment of B-Cell Malignancies. Current Pharmaceutical Design, 2008, 14, 2023-2039.	1.9	20
108	Release of IFNÎ ³ by Acute Myeloid Leukemia Cells Remodels Bone Marrow Immune Microenvironment by Inducing Regulatory T Cells. Clinical Cancer Research, 2022, 28, 3141-3155.	7.0	20

#	Article	IF	Citations
109	Mast cells contribute to autoimmune diabetes by releasing interleukin-6 and failing to acquire a tolerogenic IL-10+ phenotype. Clinical Immunology, 2017, 178, 29-38.	3.2	19
110	IF116Expression Is Related to Selected Transcription Factors during B-Cell Differentiation. Journal of Immunology Research, 2015, 2015, 1-20.	2.2	18
111	A new approach for the treatment of CLL using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles. Nano Research, 2016, 9, 537-548.	10.4	17
112	Humoral immunotherapy of multiple myeloma: perspectives and perplexities. Expert Opinion on Biological Therapy, 2010, 10, 863-873.	3.1	16
113	Microenvironment-Centred Dynamics in Aggressive B-Cell Lymphomas. Advances in Hematology, 2012, 2012, 1-12.	1.0	15
114	Targeting COPZ1 non-oncogene addiction counteracts the viability of thyroid tumor cells. Cancer Letters, 2017, 410, 201-211.	7.2	15
115	Microenvironment modulation and enhancement of antilymphoma therapy by the heparanase inhibitor roneparstat. Hematological Oncology, 2018, 36, 360-362.	1.7	15
116	The prolyl-isomerase PIN1 is essential for nuclear Lamin-B structure and function and protects heterochromatin under mechanical stress. Cell Reports, 2021, 36, 109694.	6.4	15
117	PDâ€1â€induced T cell exhaustion is controlled by a Drp1â€dependent mechanism. Molecular Oncology, 2022, 16, 188-205.	4.6	15
118	Identification of CD162 in plasma-cell dyscrasia. Lancet Oncology, The, 2005, 6, 632.	10.7	14
119	Assessment of the frequency of additional cancers in patients with splenic marginal zone lymphoma. European Journal of Haematology, 2006, 76, 134-140.	2.2	14
120	Thyroid Sarcoidosis as a Unique Localization. Thyroid, 2006, 16, 1175.	4.5	13
121	Microenvironmental regulation of the IL-23R/IL-23 axis overrides chronic lymphocytic leukemia indolence. Science Translational Medicine, 2018, 10 , .	12.4	13
122	Liver Follicular Helper T-Cells Predict the Achievement of Virological Response following Interferon-Based Treatment in HCV-Infected Patients. Antiviral Therapy, 2012, 17, 111-118.	1.0	12
123	Technical Advance: Soluble OX40 molecule mimics regulatory T cell modulatory activity on FcÉ>RI-dependent mast cell degranulation. Journal of Leukocyte Biology, 2011, 90, 831-838.	3.3	12
124	Tuning gut microbiota through a probiotic blend in gemcitabineâ€treated pancreatic cancer xenografted mice. Clinical and Translational Medicine, 2021, 11, e580.	4.0	12
125	Imatinib Spares cKit-Expressing Prostate Neuroendocrine Tumors, whereas Kills Seminal Vesicle Epithelial–Stromal Tumors by Targeting PDGFR-β. Molecular Cancer Therapeutics, 2017, 16, 365-375.	4.1	11
126	Conceptual design of the main Ancillary Systems of the ITER Water Cooled Lithium Lead Test Blanket System. Fusion Engineering and Design, 2021, 167, 112345.	1.9	11

#	Article	IF	CITATIONS
127	Castration-Induced Downregulation of SPARC in Stromal Cells Drives Neuroendocrine Differentiation of Prostate Cancer. Cancer Research, 2021, 81, 4257-4274.	0.9	11
128	Papuloâ€purpuric dermatitis of childhood: a distinct PLEVAâ€like eruption associated to SARSâ€CoVâ€2 infection. Clinical, histopathological and immunohistochemical study of 10 cases. Pediatric Dermatology, 2021, 38, 1185-1190.	0.9	11
129	Antibodyâ€mediated blockade of JMJD6 interaction with collagen I exerts antifibrotic and antimetastatic activities. FASEB Journal, 2017, 31, 5356-5370.	0.5	10
130	Real-time detection of BRAF V600E mutation from archival hairy cell leukemia FFPE tissue by nanopore sequencing. Molecular Biology Reports, 2018, 45, 1-7.	2.3	10
131	Time for a "Plan B―in Peritoneal Metastatic Disease. Cancer Research, 2019, 79, 5-6.	0.9	10
132	Response-Guided ABVD Chemotherapy plus Involved-Field Radiation Therapy for Intermediate-Stage Hodgkin Lymphoma in the Pre–Positron Emission Tomography Era: A Gruppo Italiano Studio Linfomi (GISL) Prospective Trial. Clinical Lymphoma and Myeloma, 2009, 9, 138-144.	1.4	9
133	Sistemic calciphylaxis and thrombotic microangiopathy in a kidney transplant patient: Two mixing fatal syndromes?. Medical Hypotheses, 2012, 79, 74-75.	1.5	9
134	A novel CXCR4 antagonist counteracts paradoxical generation of cisplatin-induced pro-metastatic niches in lung cancer. Molecular Therapy, 2021, 29, 2963-2978.	8.2	9
135	A ceRNA approach may unveil unexpected contributors to deletion syndromes, the model of 5q-syndrome. Oncoscience, 2015, 2, 872-879.	2.2	9
136	Genetic deletion of osteopontin in TRAMP mice skews prostate carcinogenesis from adenocarcinoma to aggressive human-like neuroendocrine cancers. Oncotarget, 2016, 7, 3905-3920.	1.8	9
137	A complex case of fatal calciphylaxis in a female patient with hyperparathyroidism secondary to end stage renal disease of graft and coexistence of haemolytic uremic syndrome. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2012, 156, 262-265.	0.6	9
138	Reciprocal influence of B cells and tumor macro and microenvironments in the <i> Apc < sup > Min/+ </i> > model of colorectal cancer. Oncolmmunology, 2017, 6, e1336593.	4.6	8
139	Burkitt lymphoma with a granulomatous reaction: an M1/Th1â€polarised microenvironment is associated with controlled growth and spontaneous regression. Histopathology, 2022, 80, 430-442.	2.9	8
140	T Cell Large Granular Lymphocytic Leukemia in Association with Sjögren's Syndrome. Acta Haematologica, 2010, 124, 5-8.	1.4	7
141	Exploratory Study on the Effects of Biodegradable Nanoparticles with Drugs on Malignant B Cells and on a Human/Mouse Model of Burkitt Lymphoma. Current Clinical Pharmacology, 2010, 5, 246-250.	0.6	6
142	IL-25 dampens the growth of human germinal center-derived B-cell non Hodgkin Lymphoma by curtailing neoangiogenesis. Oncolmmunology, 2018, 7, e1397249.	4.6	6
143	Definition of model-based control strategies for the Molten Salt Fast Reactor nuclear power plant. Nuclear Engineering and Design, 2021, 373, 111015.	1.7	6
144	Newly-Discovered Neural Features Expand the Pathobiological Knowledge of Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancers, 2021, 13, 4680.	3.7	6

#	Article	IF	Citations
145	Constant Detection of Cyclooxygenase 2 in Terminal Stages of Myeloid Maturation. Acta Haematologica, 2007, 117, 48-50.	1.4	5
146	Progressive visceral leishmaniasis misdiagnosed as cirrhosis of the liver: a case report. Journal of Medical Case Reports, 2009, 3, 7265.	0.8	5
147	SNPs Array Karyotyping Reveals a Novel Recurrent 20p13 Amplification in Primary Myelofibrosis. PLoS ONE, 2011, 6, e27560.	2.5	5
148	Development of a control-oriented power plant simulator for the molten salt fast reactor. EPJ Nuclear Sciences & Technologies, 2019, 5, 13.	0.7	5
149	SPARC regulation of PMN clearance protects from pristane-induced lupus and rheumatoid arthritis. IScience, 2021, 24, 102510.	4.1	5
150	Neutrophil extracellular traps arm DC vaccination against NPM-mutant myeloproliferation. ELife, 2022, 11 , .	6.0	5
151	Mesenchymal stem cells display hepato-protective activity in lymphoma bearing xenografts. Investigational New Drugs, 2012, 30, 803-807.	2.6	4
152	Ultrasound-guided intra-tumor injection of combined immunotherapy cures mice from orthotopic prostate cancer. Cancer Immunology, Immunotherapy, 2013, 62, 1811-1819.	4.2	3
153	The ins and outs of osteopontin. Oncolmmunology, 2015, 4, e978711.	4.6	3
154	Response to Villanacci et al American Journal of Gastroenterology, 2013, 108, 620.	0.4	2
155	Alteration of HSC Functions in Thalassemia. Blood, 2015, 126, 4752-4752.	1.4	2
156	Gene Expression Analysis Uncovers Similarity and Differences Among Burkitt Lymphoma Subtypes. Blood, 2010, 116, 2494-2494.	1.4	2
157	MEF2C and SOCS2 in stemness regulation. Oncoscience, 2015, 2, 936-937.	2.2	2
158	Small Bowel Angiodysplasia Associated with von Willebrand's Disease: Report of a Case. Surgery Today, 2006, 36, 659-662.	1.5	1
159	Is local complement activation involved in renal damage in patients with atypical haemolytic uraemic syndrome?. Molecular Immunology, 2008, 45, 4101-4102.	2.2	1
160	Arginase 1 Is a Marker of Myeloid-Mediated Immunosuppression with Prognostic Meaning in Classic Hodgkin Lymphoma. Blood, 2016, 128, 1770-1770.	1.4	1
161	Microenvironment Regulation of IL23R/IL-23 Axis Drives Chronic Lymphocytic Leukemia (CLL) Progression. Blood, 2015, 126, 616-616.	1.4	1
162	Targeting a Specific Glycosylated Epitope of CD43 with a New Humanized Monoclonal Antibody for the Treatment of Pediatric and Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL). Blood, 2018, 132, 1418-1418.	1.4	1

#	Article	IF	Citations
163	Re: ?Splenic marginal zone B-cell lymphoma associated with primary Sj�gren?s syndrome?. Clinical Rheumatology, 2005, 24, 187-187.	2.2	0
164	Reply to Pich et al.: intrasinusoidal bone marrow infiltration and splenic marginal zone lymphoma: a quantitative study. European Journal of Haematology, 2006, 77, 360-360.	2.2	0
165	Distribution and function of the complement protein C1q in malignant pleural mesothelioma microenvironment. Molecular Immunology, 2017, 89, 121.	2.2	0
166	CD73-Generated Extracellular Adenosine Creates Microenvironmental Conditions Favoring Growth and Survival of Chronic Lymphocytic Leukemia Cells. Blood, 2011, 118, 621-621.	1.4	0
167	Abstract 2997: Peripheral T-cell lymphomas not otherwise specified correspond to distinct mature T-cell populations basing on the global gene expression profile. , 2012, , .		0
168	New Therapeutic Approach for the Treatment of B-Cell Disorders Using Chlorambucil/Hydroxychloroquine-Loaded AntiCD20 Nanoparticles. Blood, 2012, 120, 158-158.	1.4	0
169	Abstract 2362: Identification and characterization of pathogenetic pathways and potential therapeutic targets in tumors derived from histiocytes and follicular dendritic cells. , 2014, , .		0
170	Abstract A42: miR34a: A valuable indicator of differential outcome of Ewing sarcoma patients with complex functions. , 2014, , .		0
171	OX40 expression in tumor-associated Tregs as a potential prognostic biomarker and immunotherapeutic target in ovarian cancer Journal of Clinical Oncology, 2015, 33, e16576-e16576.	1.6	0
172	Abstract 4054: Mast cells contribute to T cell tolerance against prostate cancer- associated antigens favoring tumor growth. , 2015, , .		0
173	Abstract B157: OX40 expression in tumor-associated Tregs as a potential prognostic biomarker and immunotherapeutic target in ovarian cancer. , 2016, , .		0
174	Abstract A18: miR-9 and miR-200 regulate PDGFR \hat{l}^2 -mediated endothelial differentiation of neoplastic cells in triple-negative breast cancer. , 2016, , .		0
175	Abstract 3289: Microenvironment modulation and enhancement of cytotoxic therapy by the heparanase inhibitor Roneparstat against human B-non Hodgkin lymphomas., 2016,,.		0
176	Abstract 5437: miR-302b as adjuvant therapeutic tool to improve chemotherapy efficacy in human triple-negative breast cancer. , 2017, , .		0
177	Abstract 4981: Circulating mir-320 promotes immunosuppressive macrophages M2 phenotype associated with lung cancer progression. , 2018, , .		0
178	Abstract 2141: Stromal SPARC deficiency skews prostate cancer toward neuroendocrine differentiation. , 2018, , .		0
179	Hematopoietic Stem Cell Function in \hat{l}^2 -Thalassemia Is Impaired and Is Rescued By Targeting the Bone Marrow Niche. Blood, 2019, 134, 967-967.	1.4	0
180	Abstract 1106: Cisplatin-induced activation of SDF-1/CXCR4 axis sustains lung cancer metastasis by promoting co-recruitment of metastasis initiating cells and inflammatory monocytes. , 2020, , .		0

#	Article	IF	CITATIONS
181	A tribute to Juan Rosai. Pathologica, 2021, 113, 302-304.	3.4	0
182	Abstract 4959: The gut microbiota contributes to the effectiveness of HER2-targeted therapy. , 2019, , .		0